Subscribe

News
Media
Conferences
Publications
Events
CE
Resources
Subscribe

Spotlight -

Community/Retail|

Pharmacy Technician|

Henry J. Henk, PhD

Articles by Henry J. Henk, PhD

Costs Associated With Second-Line Therapies for Lung Cancer

ByStephen Lash, PharmD,April Teitelbaum, MD,Henry J. Henk, PhD,Carolina M. Reyes, PhD,Lucinda Benn, MBA

February 2nd 2011

Erlotinib may confer an economic advantage for payers over docetaxel and pemetrexed for second-line treatment of lung cancer because of lower costs.

Latest Updated Articles

Costs Associated With Second-Line Therapies for Lung Cancer
Published: February 2nd 2011 | Updated:

Trending on Pharmacy Times

Breaking News: CVS Buys Rite Aid, Bartell Drugs

Amivantamab for EGFR-Mutated Metastatic Non–Small Cell Lung Cancer

Young Women With Symptomatic Long COVID At Higher Risk of POTS

FDA Approves 1-Minute HIV Self-Test

Kellermensch: Living With the Emotional Weight of a Career in Health Care

© 2025 MJH Life Sciences^®

All rights reserved.